1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY PRODUCT
5.1. Introduction
5.2. Metered-dose inhalers (MDIs)
5.3. Dry Powder Inhalers (DPIs)
5.4. Soft mist inhaler (SMI)
5.5. Nebulizers
6. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY FORMULATION TYPE
6.1. Introduction
6.2. Suspension Aerosol
6.3. Solution Aerosol
6.4. Dry Powder Formulation
7. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY APPLICATION
7.1. Introduction
7.2. Asthma
7.3. Chronic Obstructive Pulmonary Disease (COPD)
7.4. Cystic Fibrosis
7.5. Allergic Rhinitis
7.6. Other Respiratory Conditions
8. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY END-USER INDUSTRY
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Homecare Settings
8.4. Diagnostic Centers
8.5. Others
9. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY DISTRIBUTION CHANNEL INDUSTRY
9.1. Introduction
9.2. Offline
9.3. Online
10. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. USA
10.2.2. Canada
10.2.3. Mexico
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Others
10.4. Europe
10.4.1. United Kingdom
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Others
10.5. Middle East and Africa
10.5.1. Saudi Arabia
10.5.2. UAE
10.5.3. Others
10.6. Asia Pacific
10.6.1. China
10.6.2. Japan
10.6.3. India
10.6.4. South Korea
10.6.5. Taiwan
10.6.6. Thailand
10.6.7. Indosneisa
10.6.8. Others
11. COMPETITIVE ENVIRONMENT AND ANALYSIS
11.1. Major Players and Strategy Analysis
11.2. Market Share Analysis
11.3. Mergers, Acquisitions, Agreements, and Collaborations
11.4. Competitive Dashboard
12. COMPANY PROFILES
12.1. Philips Respironics
12.2. GlaxoSmithKline PLC
12.3. Boehringer Ingelheim GmbH
12.4. Teva Pharmaceutical Industries Ltd.
12.5. AptarGroup, Inc.
12.6. PARI GmbH
12.7. F. Hoffmann-La Roche AG
12.8. Gilbert Technologies
12.9. AstraZeneca PLC
13. APPENDIX
13.1. Currency
13.2. Assumptions
13.3. Base and Forecast Years Timeline
13.4. Key Benefits for the Stakeholders
13.5. Research Methodology
13.6. Abbreviations